Rachna

Recent reports that NICE was to be bypassed by drugs which were “innovative,” with funding from a new separate budget, sent me in search of the source report – the Life Sciences Blueprint, a statement from the Office of Life Sciences . This report outlines three “issues” relating to NICE, each with an OLS “solution.” (The entire report is written in that format.) The first issue concerns drugs for small populations with the potential for improved outcomes but which lack data to demonstrate

Here is the original:
James Raftery: Bypassing NICE for the sake of innovation?